January 30, 2025
The Second Circuit on Thursday declined to revive an investor suit alleging a merger between Sumitomo Pharma America Inc. and Myovant Sciences Ltd. was undervalued because the lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest.
January 02, 2024
Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest.
November 02, 2023
Executives of Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have urged a New York federal judge to toss a proposed class action claiming the companies' merger was undervalued because lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest, saying the complaint doesn't show any actual conflicts to begin with.
October 11, 2023
Two firms have been named lead counsel for a proposed class action against Myovant Sciences Ltd. and Sumitomo Pharma America Inc. claiming lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate a merger between the pharmaceutical companies had undisclosed conflicts that resulted in a low-value deal, causing losses to Myovant minority shareholders.
September 14, 2023
Pharmaceutical companies Myovant Sciences Ltd. and Sumitomo Pharma American Inc. were sued by a shareholder alleging that lawyers from Skadden Arps Slate Meagher & Flom who helped negotiate a merger between the companies had undisclosed conflicts that resulted in lost value to Myovant minority shareholders after the deal went through at what they called a suboptimal price.